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Abstract
Losartan was found to affect both the thermotropic behavior and molecular mobility of dimyristoyl- and dipalmitoyl-
phosphatidylcholine membranes (Theodoropoulou and Marsh, Biochim. Biophys. Acta 1461 (1999) 135^146). At low
concentrations, the antagonist is located close to the interfacial region of the phosphatidylcholine bilayer while at high mole
fractions it inserts deeper in the bilayers. In the present study, we investigated the interactions of losartan with
phosphatidylethanolamine membranes using differential scanning calorimetry (DSC), electron spin resonance (ESR) and 31P
nuclear magnetic resonance (NMR) spectroscopy. DSC showed that the antagonist affected the thermotropic transitions of
dimyristoyl-, dipalmitoyl- and dielaidoyl-phosphatidylethanolamine membranes (DMPE, DPPE and DEPE, respectively).
ESR spectroscopy showed that the interaction of losartan with phosphatidylethanolamine membranes is more superficial
than in the case of phosphatidylcholine bilayers. Additionally, losartan increased the spin-spin broadening of 12-PESL spin
labels in the gel phase of DMPE and DPPE membranes, while in the case of DEPE membranes the opposite effect was
observed. 31P-NMR showed that the antagonist stabilizes the fluid lamellar phase of DEPE membranes relative to the
hexagonal HII phase. Our results show that losartan affects the thermotropic behavior of phosphatidylethanolamine
membranes, while the molecular mobility of the membranes is not affected greatly. Furthermore, its interactions with
phosphatidylethanolamine membranes are more superficial than with phosphatidylcholine bilayers. ß 2000 Elsevier Sci-
ence B.V. All rights reserved.
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spectroscopy; Nuclear magnetic resonance spectroscopy
1. Introduction
Hypertension is one of the most frequently seen
cardiovascular diseases with a high factor of mortal-
ity. The regulation of blood pressure as well as the
£uid and electrolyte balance are importantly a¡ected
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by angiotensin II (ANG II), the body’s most potent
vasoconstrictor, produced by the renin^angiotensin
system (RAS).
One approach for the development of antihyper-
tensive drugs was the intervention in the RAS at the
stage of ANG II’s synthesis, using renin or angioten-
sin converting enzyme (ACE) inhibitors [1,2]. ACE
inhibitors were shown to be clinically e¡ective in the
treatment of hypertension and congestive heart fail-
ure [3]. However, this approach was found to su¡er
side e¡ects [4,5].
The most selective method for the treatment of
hypertension would be the antagonism of ANG II
at its receptor. Many peptide analogs of ANG II
itself, with varying degrees of agonist and antagonist
properties, were synthesized for this purpose. A pro-
totype of this type of receptor antagonists is saralasin
(Sar1Ile8-ANG II), which was extensively studied
preclinically [6] and was shown to lower blood pres-
sure in humans [7]. However, the therapeutic utility
of this drug was limited by the need for parenteral
administration and the presence of agonist e¡ects in
23% of the patients [8]. The breakthrough came with
the discovery of non-peptide ANG II receptor antag-
onists in 1982 by Takeda Chemical Industries [9].
Novel series of molecules were designed after the
original patent publications, which led to the discov-
ery of the prototype compound losartan (DUP 753,
MK 954) by Du Pont Merck Pharmaceutical Com-
pany [10,11].
Analysis of receptors with single-residue and com-
bined mutations revealed that speci¢c amino acid
residues in transmembrane domains III, IV, V, VI
and VII are involved in binding of losartan to the
mammalian AT1 receptor. Furthermore, despite their
locations on di¡erent transmembrane domains, most
of these residues are positioned within a small dis-
tance of each other within the plasma membrane,
suggesting that the antagonist binds to the mamma-
lian AT1 receptor in a plane that is one or two K-
helical turns below the membrane surface [12,13]. A
drug may reach a binding site on a membrane-asso-
ciated receptor protein by direct di¡usion through
the aqueous surroundings or by partitioning into
the lipid bilayer and then laterally di¡using to the
active site. The highly ordered structure of the lipid
bilayer may restrict lipophilic or amphiphilic drugs
to a particular depth of penetration in the bilayer; a
drug positioned at the proper depth of penetration
for optimal reaction with a receptor site would be an
active molecule. The orientation of the drug within
the membrane and its conformation when it enters
the bilayer are also very important features for the
interaction with the active site of the receptor [14].
Therefore, the investigation of losartan’s interactions
with the phospholipid bilayer component of mem-
branes becomes essential because the major determi-
nants of losartan binding appear to be residues
located within the transmembrane regions while
there is no contribution from the extracellular do-
mains.
In our previous study, we investigated the interac-
tions of losartan with phosphatidylcholine bilayers,
using a combination of di¡erential scanning calorim-
etry (DSC) and electron spin resonance spectroscopy
(ESR) [15]. The phosphatidylcholines used were
DMPC and DPPC that are saturated and di¡er
only in the length of their acyl chains. We selected
these two phospholipids because they are those most
extensively characterized, using DSC and ESR spec-
troscopy. Speci¢cally, we chose DMPC and DPPC
also because they exhibit single, highly cooperative
gel to liquid-crystalline phase transitions at 23.8‡C
and 41.2‡C, respectively, temperatures well above
the freezing point of water and below the melting
point of losartan (267^269‡C). It was shown, in
this former study, that losartan interacts with phos-
phatidylcholine membranes by a¡ecting both their
thermotropic behavior and their molecular mobility.
Particularly striking was the e¡ect of high concentra-
tions of the antagonist on the chain-melting behavior
of DMPC and the associated changes in vesicular
structure that were induced in this region. At low
concentrations, the antagonist seemed to be located
close to the interfacial region of the phosphatidylcho-
line bilayer, while at high mole fractions it inserted
deeper into the lipid bilayers. These results opened
up the possibility that losartan, besides its antagonist
action on the receptor level, could exert some of its
e¡ects through its interaction with the lipids of the
membrane bilayer. A more limited DSC study pub-
lished previously [16] was qualitatively consistent
with our studies on phosphatidylcholines [15].
The ¢nding that losartan intercalates close to the
interfacial region of the phosphatidylcholine bilayer
now led us to investigate the mode of losartan asso-
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ciation with bilayers formed by zwitterionic phos-
pholipids with a di¡erent headgroup. In the present
study, we investigated the interactions of losartan
with phosphatidylethanolamine membranes. Phos-
phatidylethanolamine is a major component of
both eukaryotic and prokaryotic membranes. A com-
bination of DSC, ESR and 31P-nuclear magnetic res-
onance (31P-NMR) spectroscopy was used. These
biophysical techniques can give complementary in-
formation about the thermotropic and dynamic
properties of biologically active molecules in mem-
branes [15,17^28].
2. Materials and methods
2.1. Materials
Dimyristoyl- and dipalmitoyl-phosphatidyletha-
nolamine (DMPE and DPPE, respectively) were ob-
tained from Fluka Chemical Co. (Buchs, Switzer-
land). Dielaidoyl-phosphatidylethanolamine (DEPE)
was obtained from Avanti Polar Lipids Inc. (Bir-
mingham, AL, USA). Losartan was kindly provided
by Merck’s Research Laboratories (MSD Sharp and
Dohme GmbH, Haar, Germany). Phosphatidyletha-
nolamine spin labels (n-PESL) were synthesized by B.
Angerstein as described [29].
2.2. DSC and ESR spectroscopy
Sample preparation, and calorimetric and ESR
measurements were performed as described in our
previous publication [15]. Brie£y, the dried mixtures
of phospholipids and losartan were prepared by ¢rst
codissolving appropriate amounts of the lipid and
the antagonist in a dichloromethane/methanol mix-
ture (2:1 v/v). For the preparation of DSC samples,
7 mg of the phospholipid was used, while in the case
of ESR spectroscopy, 1 mg of the phospholipid was
used and 1 mol% of the spin-labeled lipid in di-
chloromethane was added. The organic solvent was
then evaporated under a stream of oxygen-free N2, at
a temperature above the corresponding phase transi-
tion temperature of the phospholipid. The lipid/drug
mixtures were then dried under high vacuum over-
night. The dried samples were hydrated with double
distilled and deionized water (200 Wl and 50 Wl for
DSC calorimetry and ESR spectroscopy, respec-
tively).
Outer hyper¢ne splittings (2Amax) were used to
characterize the rotational disorder and rotational
rates of the spin-labeled lipid chain segments [30].
This quantity is de¢ned on the experimental spectra
given subsequently (Fig. 3). In general, the values of
2Amax will depend both on the order parameter of
the spin-labeled chain segment and on rotational cor-
relation time. For £uid-phase membranes, it will de-
pend most strongly on the chain order, but in gel-
phase membranes it will also depend strongly on the
(slow) rotational rates. For rotational mobility with
components in the slow-motional regime [31], the
change in this parameter, vAmax, therefore provides
a useful measure of the change in lipid chain mobility
induced by losartan. Rapid isotropic rotation reduces
Amax to A0 = 15.0 G, which is the isotropic average
hyper¢ne coupling constant [24]. Therefore, vAmax/
(Amax3A0) is the appropriate normalized quantity
that characterizes the changes in Amax.
2.3. 31P-NMR spectroscopy
31P-NMR spectra of hydrated pure DEPE and
mixtures with losartan incorporated at mole fractions
of x = 0.05 and x = 0.20 were obtained. Dried mix-
tures of phospholipid and losartan were prepared
following the same procedure as used for DSC sam-
ples [15]. In the case of samples for 31P-NMR spec-
troscopy, 50 mg of the phospholipid and appropriate
amounts of the antagonist were used. After hydra-
tion with 2 ml distilled and deionized water, the sam-
ples were transferred to 10 mm NMR tubes and
centrifuged for 30 min in a benchtop centrifuge at
3000 rpm. The excess water was removed prior to
acquisition of the spectra. In this way, the concen-
trated, fully hydrated lipid could be centered opti-
mally in the NMR coil.
Proton dipolar decoupled 31P-NMR spectra were
recorded at 121.5 MHz on a Bruker MSL-300 spec-
trometer operating in the Fourier transform mode.
All data were collected using one pulse acquisition
with quadrature phase cycle sequence provided in the
Bruker library of pulse programs. The 90‡ pulse used
was 11 Ws and the recycle delay 4 s. Prior to acqui-
sition, the samples were held above their phase tran-
sition temperature for 10 min to ensure complete
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hydration. The spectra were obtained over the tem-
perature range 50^86‡C. The samples were held for
15 min at each temperature before recording the
spectrum, to ensure thermal equilibration. Temper-
ature was regulated by a thermostated nitrogen gas
£ow system. Each spectrum was an accumulation of
800 scans. All chemical shift values are referenced to
85% phosphoric acid (0 ppm). Prior to Fourier trans-
formation, a trapezoidal multiplication was per-
formed using Bruker software packages (TM1 = 0
and TM2 = 50).
3. Results
3.1. DSC
The DSC traces of DMPE preparations containing
increasing concentrations of losartan are shown in
Fig. 1A. The hydrated pure DMPE undergoes a gel
to liquid-crystalline phase transition centered at
50.0‡C, in agreement with previous reports [32].
The incorporation of increasing concentrations of
the antagonist results in a progressive shift of the
observed transition to lower temperatures and a
broadening of the corresponding peak (Table 1). As
shown in Table 1, the presence of losartan does not
a¡ect very signi¢cantly the total enthalpy change
(vH) of the observed phase transition. At mole frac-
tion x = 0.05, a shoulder at the lower temperature
side of the endotherm is formed. As the concentra-
tion of the antagonist is increased to x = 0.50, this
shoulder and the whole transition is shifted to lower
temperatures.
The e¡ect of the ANG II antagonist on the ther-
motropic phase transition of DPPE is also shown in
Fig. 1B. DPPE bilayers show a phase transition from
the gel to the liquid-crystalline phase at 63.9‡C, in
agreement with previous reports [32]. Similar e¡ects
to those described for DMPE membranes are ob-
tained when the antagonist is incorporated in
DPPE membranes. The presence of losartan results
in a broadening of the phase transition peak and a
shift to lower temperatures (Table 1). The total en-
thalpy change of the observed phase transition was
little a¡ected by the incorporation of the antagonist
up to mole fractions x = 0.40 (Table 1). Only at
x = 0.50 is there an increase in vH for DPPE, which
is not observed for DMPE. Furthermore, at mole
fractions xv0.10, a low temperature shoulder is ob-
Fig. 1. DSC thermograms of hydrated DMPE (A) or DPPE (B) membranes containing losartan at the di¡erent mole fractions, x, in-
dicated. Note that the extent of the temperature scales di¡ers in (A) and (B).
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served. As the drug concentration is increased, the
shoulder is shifted to lower temperatures.
The DSC thermograms of hydrated pure DEPE
and mixtures with losartan are shown in Fig. 2.
The aqueous dispersions of DEPE undergo a gel to
liquid-crystalline phase transition in the lamellar
phase at 37.8‡C (Fig. 2A) and a lamellar to inverted
hexagonal HII structural phase transition at 61.8‡C
(Fig. 2B), in agreement with previous data [33]. In-
creasing concentration of losartan produces a broad-
ening of the peak that corresponds to the gel to liq-
uid-crystalline phase transition and a progressive
shift in the transition to lower temperatures (Table
2). The progressive broadening of the transition,
which is greater than that for the saturated DMPE
and DPPE lipids at the higher losartan concentra-
tion, corresponds to a decreasing cooperativity of
the chain melting. At mole fractions xv 0.01 a
shoulder at the lower temperature side of the endo-
therm is observed, as in the case of the thermograms
of DMPE and DPPE membranes containing the an-
tagonist. The lamellar to inverted hexagonal HII
phase transition is shifted to higher temperatures as
the concentration of losartan increases to x = 0.20,
while at higher drug mole fractions, this transition
is not observed at temperatures up to 80‡C (Table 2).
3.2. ESR spectroscopy
ESR spectra of phosphatidylethanolamines spin-
labeled at the 5-, 12- or 14-position of the sn-2 chain
(5-PESL, 12-PESL and 14-PESL, respectively) incor-
porated in DMPE bilayers are compared in Fig. 3
(dotted lines) with the corresponding ones from prep-
arations containing losartan at x = 0.20 (solid lines).
The spectra were obtained at di¡erent temperatures
Table 1
Calorimetric peak temperatures (Tc), half-widths (vTc1=2) and
total enthalpy changes (vH) of DMPE or DPPE bilayers con-
taining di¡erent concentrations of losartan
Sample Tc (‡C)a vH
(kcal/mol)a
vTc1=2
(‡C)a
DMPE, DPPE 50.0 63.9 5.1 7.3 0.5 0.4
+losartan (x = 0.01) 49.9 63.9 5.3 6.9 0.5 0.4
+losartan (x = 0.05) 49.6 63.8 5.4 6.8 0.8 0.5
+losartan (x = 0.10) 49.5 63.5 5.2 7.0 1.0 0.7
+losartan (x = 0.20) 48.8 63.3 5.4 7.4 1.9 0.6
+losartan (x = 0.40) 47.4 62.4 5.1 7.4 1.6 0.6
+losartan (x = 0.50) 46.6 62.0 5.6 8.6 1.0 0.7
aValues in the left-hand column correspond to DMPE bilayers
and those on the right to DPPE bilayers.
Fig. 2. DSC thermograms of hydrated dispersions of DEPE containing losartan at the di¡erent mole fractions, x, indicated.
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in order to cover di¡erent lamellar phases of the
phosphatidylethanolamine membranes.
In the case of 5-PESL spin labels, DMPE bilayers
exhibit a chain-melting phase transition in the region
around 45‡C, as is observed from the two-compo-
nent spectra and the decrease in the outer hyper¢ne
splitting 2Amax (vAmax/(Amax3A0) = 41.4% between
40 and 50‡C). The bilayers containing losartan ex-
hibit this transition at around 40‡C (vAmax/
(Amax3A0) = 53.8% between 35 and 45‡C). The mo-
bility of the spin label is not a¡ected by the antago-
nist (at x = 0.20) either in the gel or in the liquid-
crystalline phase, as is concluded from the near iden-
tity of the spectra and the observation that the outer
hyper¢ne splitting 2Amax of the spectra is not a¡ected
by the incorporation of losartan into DMPE mem-
branes. As is evident in Fig. 3, the spin-spin broad-
ening of the 12-PESL spin labels in the gel phase of
DMPE bilayers is increased somewhat by the pres-
ence of losartan in the membranes. Spin-spin broad-
ening arises from mutual interactions between spin
labels and only occurs at high local concentrations of
the (otherwise dilute) spin-labeled lipids. The in-
crease in spin-spin broadening therefore demon-
strates that losartan increases the partial exclusion
of the spin-labeled phospholipids from the tightly
packed DMPE molecules in the gel phase. The ob-
served phase transition is also shifted to between 40
and 45‡C (vAmax/(Amax3A0) = 77.8% between 40 and
Table 2
Calorimetric peak temperatures (Tc), half-widths (vTc1=2) and
total enthalpy changes (vH) of DEPE dispersions containing
di¡erent concentrations of losartan
Sample Tc (‡C)a vH
(kcal/mol)a
vTc1=2
(‡C)a
DEPE 37.8 61.8 7.0 0.5 0.3 0.9
+losartan (x = 0.01) 37.4 63.4 7.2 0.5 0.6 0.9
+losartan (x = 0.05) 37.0 66.9 7.2 0.4 0.9 1.2
+losartan (x = 0.10) 36.5 70.1 7.0 0.2 1.3 1.5
+losartan (x = 0.20) 35.5 77.1 6.5 0.4 1.3 2.0
+losartan (x = 0.40) 34.2 ^ 6.5 ^ 1.9 ^
+losartan (x = 0.50) 32.7 ^ 9.4 ^ 2.2 ^
aValues in the left-hand column correspond to the transition
from the lamellar gel to the lamellar liquid-crystalline phase
and those on the right to the structural phase transition from
the lamellar liquid-crystalline phase to the hexagonal HII phase.
Fig. 3. ESR spectra of 5-, 12- and 14-PESL spin labels incorporated either in DMPE membranes (dotted line) or DMPE membranes
containing losartan at mole fraction x = 0.20 (solid line) obtained at the temperatures indicated, over the range 25^50‡C for 5-PESL
and 30^50‡C for 12- and 14-PESL spin probes. The outer hyper¢ne splitting 2Amax is also indicated. Total scan width = 100 G.
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45‡C) while in pure DMPE this transition occurs at
around 47‡C (vAmax/(Amax3A0) = 71.8% between 45
and 50‡C). ESR spectra of the 14-PESL spin label
show that the preparation containing the antagonist
undergoes the chain-melting phase transition be-
tween 40 and 45‡C (vAmax/(Amax3A0) = 74.8% be-
tween 40 and 45‡C). The corresponding pure lipid
preparation undergoes this transition at around
47‡C (vAmax/(Amax3A0) = 62.4% between 45 and
50‡C). Moreover, in the presence of losartan, the
mobility of the 14-PESL spin label is increased in
the liquid-crystalline phase relative to in its absence,
as is evident from the decrease of the outer hyper¢ne
splitting 2Amax (vAmax/(Amax3A0) = 39.0% at 50‡C).
Losartan was incorporated also into DPPE mem-
branes at a mole fraction x = 0.20, and the corre-
sponding ESR spectra of 5-, 12- and 14-PESL spin
labels are shown in Fig. 4. Results qualitatively sim-
ilar to those described for the DMPE preparation
containing x = 0.20 of losartan are obtained. No ef-
fect of the antagonist on the mobility of the 5-PESL
spin label is observed either in the gel or in the £uid
phase at x = 0.20. Losartan shifts the chain-melting
transition to between 55 and 58‡C (vAmax/
(Amax3A0) = 42.8% between 53 and 60‡C), while
membranes of DPPE alone exhibit this transition
between 58 and 60‡C (vAmax/(Amax3A0) = 41.7% be-
tween 55 and 63‡C). An increase of spin-spin broad-
ening on incorporation of the antagonist in DPPE
bilayers is observed in the gel phase for the ESR
spectra of the 12-PESL spin label. The degree of
spin-spin broadening is much greater than for gel-
phase DMPE (cf. Fig. 3). This precludes precise de-
termination of the chain-melting event from the 12-
PESL spectral lineshapes. Nonetheless, a depression
of the chain-melting transition temperature by losar-
tan is evident. In the case of 14-PESL spin labels, a
shift of the chain-melting transition due to losartan
incorporation is also observed. In the preparation
containing the antagonist, this transition occurs at
around 60‡C (vAmax/(Amax3A0) = 67.7% between 58
and 63‡C), while in the pure DPPE preparation it
occurs at around 63‡C (vAmax/(Amax3A0) = 58.3%
between 60 and 65‡C). Furthermore, the mobility
Fig. 4. ESR spectra of 5-, 12- and 14-PESL spin labels incorporated either in DPPE membranes (dotted line) or DPPE membranes
containing losartan at mole fraction x = 0.20 (solid line) obtained at the temperatures indicated, over the range 45^65‡C. Total scan
width = 100 G.
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of the 14-PESL spin label is increased in the liquid-
crystalline phase by the presence of losartan (vAmax/
(Amax3A0) = 18.6% at 65‡C).
The ESR spectra obtained from the 5-, 12- and 14-
PESL spin labels incorporated in DEPE dispersions
containing losartan at mole fraction x = 0.20 (solid
lines) are compared with the corresponding ones of
DEPE preparation without the antagonist (dotted
lines) in Fig. 5. The temperature dependences of
the outer hyper¢ne splittings, 2Amax, from the spectra
of 5-PESL spin label incorporated in DEPE dis-
persions containing losartan at di¡erent concentra-
tions (x = 0.20 or x = 0.60) are given in Fig. 6. As is
evident from this ¢gure, DEPE dispersions undergo a
chain-melting transition at around 35‡C (vAmax/
(Amax3A0) = 30.3% between 30 and 36‡C). When
the antagonist is incorporated in DEPE dispersions
at mole fraction x = 0.20, this transition is shifted to
around 25‡C (vAmax/(Amax3A0) = 21.8% between 25
and 30‡C). At higher drug concentration, x = 0.60,
the transition is broadened very considerably. Fur-
thermore, in Fig. 6 a second transition is seen in
dispersions of DEPE alone, at around 60‡C. This
corresponds to the structural phase transition from
the lamellar liquid-crystalline to the inverted hexag-
onal HII phase. The transition is shifted to between
70 and 75‡C in the preparation containing losartan
at x = 0.20, while it is not detected in the preparation
containing the antagonist at x = 0.60.
At 50‡C, DEPE membranes and preparation con-
taining the antagonist at x = 0.20 are in the lamellar
liquid-crystalline phase, as is seen in the correspond-
ing thermograms (Fig. 2). The mobility of the 5-
PESL spin label is increased due to the presence of
losartan in the lamellar liquid-crystalline phase as is
seen in Fig. 5 (vAmax/(Amax3A0) = 2.4% at 50‡C). At
65‡C, the mobility of the 5-PESL spin label is, how-
ever, decreased in the preparation containing the an-
tagonist (vAmax/(Amax3A0) = 10.3%). This switch can
be explained by the di¡erent membrane organization
of the preparations with and without losartan. At
65‡C, DEPE membranes are organized in the in-
verted hexagonal HII phase while the preparation
containing losartan at mole fraction x = 0.20 is still
Fig. 5. ESR spectra of 5-, 12- and 14-PESL spin labels incorporated either in DEPE dispersions (dotted line) or DEPE dispersions
containing losartan at mole fraction x = 0.20 (solid line) obtained at the temperatures indicated, over the range 25^65‡C. Total scan
width = 100 G.
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in the lamellar liquid-crystalline phase (Fig. 2). In the
case of the 12-PESL spin label, the spin-spin broad-
ening in the gel phase of the DEPE spectra is de-
creased by addition of losartan at mole fraction
x = 0.20 (Fig. 5). In the lamellar liquid-crystalline
phase, the mobility of the 12-PESL spin label is in-
creased in the preparations containing the antagonist
(vAmax/(Amax3A0) = 4.2% at 50‡C). At 65‡C, as in
the case of the 5-PESL, the mobility of the spin label
is decreased in the membranes containing losartan
(vAmax/(Amax3A0) = 43.8%). Similar e¡ects are ob-
served in the spectra of the 14-PESL spin labels
from DEPE dispersions (Fig. 5). The mobility of
the spin label is increased in the lamellar liquid-crys-
talline phase of preparations containing the antago-
nist (vAmax/(Amax3A0) = 3.0% at 50‡C). On the other
hand, a decrease in the mobility of the 14-PESL spin
label is observed at 65‡C, when losartan is incorpo-
rated into DEPE membranes at mole fraction
x = 0.20 (vAmax/(Amax3A0) = 78.9%).
3.3. 31P-NMR spectroscopy
The e¡ect of losartan on the thermotropic phase
transitions of DEPE was further investigated by
broad-line 31P-NMR spectroscopy and the corre-
sponding proton decoupled spectra are shown in
Fig. 7. The powder line shapes of 31P-NMR spectra
from hydrated DEPE are characteristic of the struc-
tural organization of the phospholipid dispersions.
For bilayers, an asymmetrical line shape with a
high-¢eld peak and a low-¢eld shoulder is observed
[34]. When DEPE is organized in a hexagonal HII
phase, a line shape of reversed asymmetry (high-¢eld
shoulder peak and a low-¢eld peak), with a 2-fold
reduction in e¡ective chemical shift anisotropy, is
obtained [35]. As is shown in Fig. 7A, up to 65‡C,
the 31P-NMR spectra of hydrated DEPE alone are
characteristic of a bilayer membrane organization.
At higher temperatures, at least up to 86‡C, DEPE
is organized in a hexagonal HII phase, as is evident
from the powder pattern of reversed asymmetry.
When losartan is incorporated into DEPE mem-
branes at mole fraction x = 0.05 (Fig. 7B), the char-
acteristic line shape of a bilayer phase is retained up
to 68‡C. At 70‡C, a small signal appears, superim-
posed on the bilayer line shape. The resonance posi-
tion of this signal coincides with the chemical shift of
the low ¢eld peak of the hexagonal HII phase line
shape. At higher temperatures, the spectra are char-
Fig. 6. Temperature dependence of the outer hyper¢ne splitting (2Amax) of 5-PESL spin label incorporated in DEPE dispersions con-
taining losartan at di¡erent concentrations. (b) hydrated DEPE alone, (F) DEPE dispersions containing losartan at mole fraction
x = 0.20, and (8) DEPE dispersions containing losartan at mole fraction x = 0.60.
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acteristic of a hexagonal HII phase organization.
More pronounced spectral e¡ects are observed
when the antagonist is incorporated at the higher
mole fraction of x = 0.20 (Fig. 7C). At temperatures
up to 70‡C, the line shape of the spectra is character-
istic of a bilayer structure, but with evidence for
magnetic alignment of the lipid dispersion (i.e., an
increase in intensity of the cP peak at the expense
of the ce shoulder). A composite spectrum, indicative
of a mixture of phases, is observed at 85‡C, while at
86‡C a narrow isotropic peak dominates. The latter
is indicative of rapid motional averaging on the time-
scale of the 31P-NMR chemical shift anisotropy.
Such a line shape has been proposed to represent
an intermediate phase between the hexagonal HII
and the bilayer phase [35]. Isotropic 31P-NMR line
shapes are not diagnostic on this point, however.
4. Discussion
The fact that besides its action on AT1 and AT2
receptors, ANG II also interacts with the lipid bi-
layer of biological membranes and the knowledge
that the major determinants of losartan binding ap-
pear to be residues located within the transmembrane
regions III, IV, V, VI and VII of the AT1 receptor,
led us to investigate the interactions of losartan, an
AT1 ANG II antagonist, with the phospholipid bi-
layer component of membranes [15]. In our ¢rst
study, we showed that losartan interacts with phos-
phatidylcholine membranes by a¡ecting both their
thermotropic behavior and molecular mobility. Fur-
thermore, it was suggested that, at low concentra-
tions, the antagonist was located close to the inter-
facial region of the phosphatidylcholine bilayer while
at high mole fractions it was inserted deeper in the
bilayers. In the present study, we investigated the
interactions of losartan with phosphatidylethanol-
amine membranes using DSC, ESR and 31P-NMR
spectroscopy.
Phosphatidylethanolamine is the second most
abundant zwitterionic phospholipid in mammalian
cell membranes, after phosphatidylcholine. Mem-
branes composed of phosphatidylethanolamine di¡er
from those of phosphatidylcholine, however, in terms
of several important physical characteristics that are
related to di¡erences in headgroup hydration and
hydrogen bonding [36]. Here we contrast the present
results on the interactions of losartan with phospha-
tidylethanolamines with those that we obtained pre-
viously on the interactions with phosphatidylcho-
lines. The study was conducted over a wide range
of concentrations of the antagonist, extending to val-
ues that are well above the likely physiological range.
This was done in order to obtain a more complete
biophysical characterization of the membrane inter-
actions with losartan. Furthermore, it allows a more
detailed comparison with the results obtained previ-
ously with phosphatidylcholines over the same wide
compositional range. It will be noted, however, that
many of the changes induced by losartan increase
progressively with increasing concentration, and are
simply expressed with greater intensity at the higher
concentrations.
Our DSC results show that losartan a¡ects the
cooperativity in thermodynamic properties of
DMPE, DPPE and DEPE membranes by lowering
the transition temperature from the gel to the lamel-
lar liquid phase and broadening the corresponding
endothermic peak (Figs. 1 and 2). These e¡ects are
formally similar to those observed for phosphatidyl-
Fig. 7. Proton-decoupled 31P-NMR spectra of DEPE disper-
sions (A) or DEPE dispersions containing losartan at mole
fractions x = 0.05 (B) and x = 0.20 (C) obtained at the tempera-
tures indicated, over the range 50^86‡C.
BBAMEM 77982 5-12-00
E. Theodoropoulou, D. Marsh / Biochimica et Biophysica Acta 1509 (2000) 346^360 355
choline bilayers [15]. In the case of phosphatidylcho-
lines, the chain-melting behavior of the bilayers was
sensitively a¡ected by losartan. This was especially
dramatic with DMPC bilayers, for which at high
drug concentrations the thermotropic transition re-
gion was very extensively broadened and displayed
a complex endothermic behavior characterized by
three major calorimetric peaks. This behavior was
associated with changes in the vesicular structure
that were induced in this region [37]. Unlike with
DMPC, such a strong e¡ect of losartan on the ther-
motropic behavior is not observed here with DMPE.
The morphological changes accompanying the com-
plex melting behavior observed with DMPC have
been related to solvent-dependent interactions [37].
Therefore it is likely that they are not exhibited
with DMPE, as compared to DMPC, because phos-
phatidylethanolamine membranes are less highly hy-
drated than those of phosphatidylcholines [36,38]. It
is not known with certainty whether the appearance
of a shoulder on the main calorimetric endotherms of
DMPE, DPPE and DEPE at losartan concentrations
higher than x = 0.05, x = 0.10 and x = 0.01, respec-
tively (Figs. 1 and 2) is a manifestation of e¡ects
similar to those discussed for phosphatidylcholine
bilayers [15]. Interestingly, the shoulder appears on
the low-temperature side of the main endotherm
rather than on the high-temperature side, as was ob-
served with DMPC. This might correlate with the
di¡erent gel-phase structures that are known for
phosphatidylethanolamines compared with phospha-
tidylcholines.
The dependence of the peak chain-melting transi-
tion temperature, Tc, on mole fraction, x, of losartan
incorporated is given in Fig. 8 for fully hydrated
bilayers of the various phosphatidylcholine [15] and
phosphatidylethanolamine species. In each case, the
peak transition temperature decreases linearly with
increasing mole fraction of losartan. This is in accor-
dance with thermodynamic expectations for the
freezing point depression by a single solute compo-
nent. The gradient of the decrease in transition tem-
perature with mole fraction of losartan di¡ers be-
tween the di¡erent lipids. In the general case of
solute partitioning between the gel and £uid lipid
states, the depression in Tc is given by [39]:
T c  Toc3
2RTo
2
c
vHot
13K
1 K Wx 1
where R is the ideal gas constant, Toc and vH
o
t are the
transition temperature and transition enthalpy, re-
spectively, in the absence of solute, and K is the dis-
tribution coe⁄cient of the solute between gel and
£uid lipid phases. For the extreme case that the sol-
ute partitions completely into the £uid phase, then
K = 0 and the depression in transition temperature
has its maximum value.
Values of the gradient in transition temperature,
dTc/dx, with mole fraction of losartan, obtained
from linear regression are given in Table 3. All values
are considerably smaller than the theoretical maxi-
mum, i.e., 32RTo
2
c =vHt, values of which are also
given in Table 3. These are calculated from values
of Toc obtained from the linear regressions and of
Fig. 8. Dependence of the chain-melting transition temperature,
Tc, on mole fraction, x, of losartan in DMPC (b), DPPC (F),
DMPE (R), DPPE (8) and DEPE (S) bilayers. Data for
DMPC and DPPC are from [15]. In each case, the value of Tc
corresponds to the peak of the major calorimetric endotherm.
For DMPC, which displays a complex extended chain-melting
behavior, this corresponds to the major onset of chain melting.
Lines are linear regressions.
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vHot from calorimetry as described above. Clearly,
however, losartan partitions into the £uid phase in
each of the phospholipid systems. Independent evi-
dence for this, in several cases, comes from perturba-
tion of the spin-labeled lipid ESR spectra in the £uid
phase. The values of the distribution coe⁄cient K,
deduced from Eq. 1 and the data given in Fig. 8,
are also presented in Table 3. A value of K6 1 rep-
resents preferential partitioning into the £uid phase,
i.e., a lowering of the transition temperature. A value
of Ks 1 correspondingly represents a preferential
partitioning into the gel phase, i.e., an increase in
transition temperature. A direct correlation is found
between the values of K and the chain-melting tran-
sition temperature, Toc , for all lipids. Those with a
lower transition temperature favor partitioning into
the £uid lipid phase in the region of phase coexis-
tence at Tc. The most strongly enhanced e¡ect is for
DMPC, which explains why the chain-melting tran-
sition of this lipid is so e¡ectively perturbed by los-
artan, as compared with both phosphatidylethanol-
amines and longer-chain phosphatidylcholines.
Losartan also a¡ected the structural phase transi-
tion from the lamellar £uid phase to the inverted
hexagonal HII phase of DEPE, which was broadened
and shifted to higher temperatures (Fig. 2B). The
greater sensitivity of the HII transition to perturba-
tion by losartan is undoubtedly attributable to the
much lower enthalpy and entropy of this £uid^£uid
transition, relative to that for chain-melting [38]. The
direction of the shift indicates that the £uid lamellar
phase is stabilized relative to the HII phase by los-
artan. From the data given in Table 2 and Eq. 1, a
value of K = 1.2 is estimated for the preferential par-
titioning of losartan into the lamellar £uid phase,
relative to the HII phase, of DEPE dispersions.
This is consistent with a super¢cial or interfacial as-
sociation of losartan with phosphatidylethanolamine
bilayers rather than a penetration into the hydropho-
bic core. Such a location of the antagonist would
increase the lipid headgroup area and consequently
disfavor formation of the inverted HII phase. Corre-
spondingly, the accompanying perturbation of the
tight lipid packing in the gel phase, will shift the
gel to liquid-crystalline phase transition to lower
temperature.
ESR spectroscopy was performed to study the ef-
fect of losartan on the chain motion and packing in
bilayer membranes by using di¡erent positional iso-
mers of phosphatidylethanolamine (n-PESL) spin
probes incorporated in DMPE, DPPE or DEPE
membranes. The ESR spectra obtained showed that
losartan shifted the chain-melting phase transition to
lower temperatures and broadened the region of
phase coexistence, in agreement with DSC data
(Figs. 1 and 2). Although mirroring the e¡ects on
the calorimetric transition, changes in chain dynam-
ics precede the heat capacity maxima. This is a char-
acteristic feature of phosphatidylethanolamine lamel-
lae, as registered for instance by deuterium NMR
spectroscopy [40]. A shift to lower temperatures
and widening of the chain-melting region was also
induced by losartan in phosphatidylcholine bilayers
[15].
The incorporation of the antagonist in DMPE,
DPPE or DEPE membranes at mole fraction
x = 0.20 does not signi¢cantly a¡ect the chain mobil-
ity of the 5-PESL spin label (Figs. 3^5). This is con-
sistent with a more super¢cial interaction of losartan
with phosphatidylethanolamines under the condi-
tions used. Perturbation of the chain mobility is al-
most negligible in the gel and £uid phases, outside
the chain-melting transition region. These results are
in contrast to the situation with phosphatidylcholines
[15]. Even at a mole fraction x = 0.10, losartan in-
duced a decrease in chain mobility of phosphatidyl-
choline bilayers in both the gel and £uid phases.
Additionally, this change was registered more sensi-
tively by the spin label on the 5-position than by spin
labels positioned further down the chain. Because of
this observation, it was concluded that the antagonist
is located closer to the interfacial region than to the
Table 3
Dependence of chain-melting transition temperature, Tc, on
mole fraction, x, of losartan in various lipid bilayers, deduced
from linear regressiona
Lipid dTc/dx (K) 2RTo
2
c =vH t (K) K
DMPC 318.92 þ 0.21 66.10 þ 1.26 0.555 þ 0.003
DPPC ^6.60 þ 0.43 51.58 þ 0.70 0.773 þ 0.010
DMPE ^6.67 þ 0.21 81.35 þ 1.61 0.848 þ 0.002
DPPE ^3.84 þ 0.14 61.84 þ 0.85 0.883 þ 0.003
DEPE ^10.07 þ 0.65 54.75 þ 0.81 0.689 þ 0.013
adTc=dx  32RTo2c =vH t, if losartan is con¢ned to the high
temperature phase. K is the partition coe⁄cient of losartan be-
tween gel and £uid phases.
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hydrophobic core of the phosphatidylcholine bilayer.
It was proposed that one possible mode of insertion
is location of losartan’s polar hydroxyl group near
the carbonyl groups of the phospholipids, with which
it could form hydrogen bonds. This di¡erence in the
location of losartan in phosphatidylethanolamine
and phosphatidylcholine membranes could be a con-
sequence of the di¡erent degrees of hydration of the
surfaces of the membranes composed of these two
classes of lipids. Hydrogen bonding between the lipid
headgroups in phosphatidylethanolamine membranes
results in a more tightly packed and less hydrated
structure that could resist the penetration of losartan
beyond the super¢cial membrane interface.
Interestingly, the spin-spin broadening in the spec-
tra of the 12-PESL spin probe incorporated in the gel
phase of DMPE or DPPE is increased in the pres-
ence of losartan rather than being decreased as is the
corresponding situation with phosphatidylcholine bi-
layers [15]. In the gel phase of phosphatidylcholine
bilayers, the antagonist was found to improve the
solubility of the lipid probes, and possibly of other
components. This again suggests a di¡erent mode of
association with the less strongly hydrated phospha-
tidylethanolamine bilayer membranes, such that
close packing of the lipid chains is increased in the
gel phase by the presence of losartan.
At high mole fractions (x = 0.60), losartan was
found to insert deeper in the phosphatidylcholine
bilayers, a¡ecting more strongly the mobility of 14-
PCSL spin probes for DMPC and DPPC membranes
while the mobility of 5-PCSL was less a¡ected [15].
In the case of DMPE membranes, when losartan was
incorporated at high concentration (x = 0.60), the
formation of a second component in the outer wings
of the 14-PESL spin label spectra in the £uid phase
was observed (data not shown). This indicates that at
high concentrations, the antagonist is located deeper
also within DMPE bilayers. Indeed, the e¡ect is
greater in DMPE bilayers than in phosphatidylcho-
lines (speci¢cally in DMPC), because a second more
motionally restricted spectral component is not ob-
served with the 14-position labels in the latter case.
In our previous study [15], we proposed that the
deeper penetration may be caused by self-association
of losartan with intermolecular bonding of its polar
hydroxyl groups that results in a more hydrophobic
behavior of the antagonist. Self-association of losar-
tan may be enhanced in phosphatidylethanolamine
bilayers by intermolecular hydrogen bonding be-
tween the latter lipids. This, possibly together with
hydrophobic mismatch, may account for the pres-
ence of the second more motionally restricted lipid
component in DMPE bilayers, where the latter
would correspond to lipids at the interface with the
losartan complexes.
31P-NMR spectroscopy was performed to further
investigate the e¡ect of losartan on the structural
transition from the lamellar liquid-crystalline phase
to the hexagonal HII phase of DEPE membranes.
Our 31P-NMR data con¢rmed the results obtained
by DSC, showing that the presence of the antagonist
stabilizes the £uid lamellar phase relative to the HII
phase. Formation of hexagonal-phase intermediates
has been associated with membrane fusion [41]. A
substance which is located near the surface of a bi-
layer can inhibit the formation of a hexagonal phase,
as well as inhibiting membrane fusion phenomena
and other mechanisms of lipid exchange [42]. The
present results with DEPE indicate that losartan
can function in this manner.
In conclusion, our results show that losartan af-
fects the thermotropic behavior of phosphatidyletha-
nolamine membranes, while the molecular mobility
of the membranes is not signi¢cantly a¡ected, in con-
trast to the situation with phosphatidylcholine bi-
layers. Furthermore, the interactions of the antago-
nist with phosphatidylethanolamine membranes, at
least at low drug concentrations, are more super¢cial
than with phosphatidylcholine bilayers.
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